An update on the use of tolvaptan for autosomal dominant polycystic kidney disease: consensus statement on behalf of the ERA Working Group on Inherited Kidney Disorders, the European Rare Kidney Disease Reference Network and Polycystic Kidney Disease International
Roman‐Ulrich Müller(Cologne Excellence Cluster on Cellular Stress Responses in Aging Associated Diseases), Stephen B. Walsh and Ron T. Gansevoort, Tess Harris(Polycystic Kidney Disease Foundation), Roser Torrá(Universitat Autònoma de Barcelona), A. Lianne Messchendorp(University Medical Center Groningen), Patrick Guirchoun, Tom Nijenhuis(Radboud University Nijmegen), Ewout J. Hoorn(Erasmus MC), Olivier Devuyst(Cliniques Universitaires Saint-Luc), Giovambattista Capasso(Canon (Japan)), Uwe Korst, John A. Sayer(Newcastle University), Aude Servais(Hôpital Necker-Enfants Malades), Henrik Birn(Aarhus University), Djalila Mekahli(KU Leuven), Albertien M. van Eerde(Hospital Reina Sofía de Murcia), Nine V.A.M. Knoers(University Medical Center Groningen), Vladimı́r Tesař(Charles University), Émilie Cornec-Le Gall(Inserm), Yannick Le Meur(Université de Bretagne Occidentale), Franz Schaefer(Heidelberg University), Albert Ong(University of Sheffield)
Cited by 6
Related Papers
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
|Kidney International|2021|2.5k
Non-Transgenic Mouse Models of Kidney Disease
|The Nephron journals/Nephron journals|2016|1.9k
2016 European Society of Hypertension guidelines for the management of high blood pressure in children and adolescents
|Journal of Hypertension|2016|1.4k
Evolving importance of kidney disease: from subspecialty to global health burden
|The Lancet|2013|1.2k